STEMORA INC.

Medtech · Private

controlled-release biologics formulation combining microfracture surgery with growth factors to regenerate native hyaline cartilage via skeletal stem cell activation

Grants
$305K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Biochemical Modulation of Resident Skeletal Stem Cells for In Vivo Hyaline Cartilage Regeneration$305,000
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
667CHISQUARE BIOIMAGING, LLC——
668STAR VOLTAIC LLC——
669BRIOPRYME BIOLOGICS, INC.——
670STEMORA INC.——
671XCELLASSAY, INC.——
672KINIMMUNE, INC.——
673LAB TO PHARMACY LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.